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Z 7 C-cl
Coexpression of multiple ErbB receptors and EGF ligands in primary tumors complicates analysis of the cause and effect relationships between ErbB receptor expression and breast cancer. Since normal mammary epithelial cells express multiple ErbB receptors, it has not been possible to: (1) determine whether ErbB receptors have distinct roles in epithelial transformation; (2) understand the mechanisms by which distinct ErbB receptor dimers transform normal mammary epithelium. To evaluate the specific contributions of individual ErbB family members during transformation of the mammary epithelium, I combined a synthetic ligand-mediated controlled dimerization strategy and a modified cell culture approach to activate selected ErbB receptors in pre-formed acinar structures made up of growth-arrested polarized epithelial cells. I demonstrate that activation of ErbB2, but not ErbBl, within mammary acini resulted in disruption of the acinar organization and formation of large structures containing multiple acini-like units with filled luminal space similar to those observed in carcinoma in situ in vivo. Activation of ErbB2 was not sufficient to induce anchorage independence or migration/invasion suggesting that ErbB2 homodimers induce early stages of carcinogenesis in culture. Our results also suggest, for the first time, that ErbBl and ErbB2 homodimers differ in their ability to alter the polarized, growth-arrested organization of an epithelial acinus. These observations provide us with the means to study tumor progression in culture.
4: Introduction:
Receptor tyrosine kinases that belong to the ErbB family (ErbB 1/ErbB2(Her2)/ErbB3 and ErbB4) are thought to play important roles during breast cancer development and progression. There are at least 10 different ligands that regulate the function of ErbB receptors. Ligand binding results in formation of both homodimers and heterodimers among the ErbB receptors. For instance, binding of EGF to ErbB 1 will not only induce homodimerization of ErbB 1 but can also induce heterodimerization between ErbB 1 and other ErbB receptors. This results in a complex process of combinatorial signaling involving all four ErbB receptors. Coexpression of multiple ErbB receptors and EGF ligands in primary tumors complicates our ability to understand the cause and effect relationships between ErbB receptor expression and breast cancer. Since normal mammary epithelial cells express multiple ErbB receptors, it has not been possible to: (1) determine whether ErbB receptors have distinct roles in epithelial transformation; (2) understand the mechanisms by which distinct ErbB receptor dimers transform normal mammary epithelium.
5: Body:
Year 1: All three tasks have been completed. Please refer to Appendix # 2 and the 1999 annual report for details.
Year 2 &3: Taskl: I was able to establish cell lines expressing multiple ErbB receptors and determine that ErbB 1/ErbB 1 homodimers and ErbB 1/ErbB2 heterodimers differ in their ability to associate with a cytoplasmic signaling molecule c-Cbl (Appendix #2). However, due to limitation with the chemistry I was unable to obtain a heterodimering version of Rapamycin that lack the growth suppressive property. It is likely that I will soon be able to obtain a non-growth suppressive version of Rapamycin that still has its heterodimering property (ARIAD Pharmaceutical, personnel communication). We have established fibroblast cell lines that can be used to test the rapalogs. Once tested we will be able to evaluate the biological outcomes of activating specific ErbB heterodimers.
In order to begin to understand the biological effects of different ErbB receptors in mammary epithelial cells, I made sincere efforts to study ErbB receptor signaling normal mammary epithlelial cells derived from the mouse mammary gland. Those attempts were largely unsuccessful (please refer to 1999 annual report) however, I was able to conduct the studies using a normal human mammary epithelial cell line, MCF-1OA. During the past year I have successfully managed to fully establish that the synthetic ligand inducible activation system in the normal mammary epithelial cell line MCF-10A and ask relevant questions to understand the mechanisms by which normal mammary epithelial cells are transformed by ErbB receptors.
Part of my year 3 SOW outlines identification of novel heterodimer specific signaling molecules. I have reached a stage where I'll be able to distinguish the biological specificities of different ErbB dimers in normal mammary epithelial cells. Since it is important to establish the biological specificities before I begin detailed investigations on identification of novel signaling molecules/pathways I have not made significant progress with that task. Another task for year 3 is to perform initial analyses using transgenic mice expressing synthetic ligand inducible ErbB receptors. I have begun with making the necessary DNA vectors that would allow us to make transgenic mice. Once I have the DNA constructs tested, Dr. Bill Muller will be able to carry out the microinjection procedures. We have made detailed outlines about the constructs and timeline of the events during the Era of Hope meeting at Atlanta.
Results:
It is thought that loss of epithelial polarity is an early event during oncogenesis and epithelial-mesenchymal transition is a later event involved in progression towards malignancy. The analysis of oncogenesis in polarized epithelial structures allows one to evaluate this process under conditions that more closely resemble the natural environment of epithelial cells and should provide valuable information about the events involved in cancer initiation. By combining the synthetic dimerizing ligands and the modified culture system I have demonstrated, for the first time, that growth-arrested human mammary epithelial acinar structures can be used to study the early stages of carcinogenesis in culture.
My results (described in detail below) suggest that although activation of ErbB2 was not sufficient to induce anchorage-independent growth of MCF-10A cells, it was sufficient to affect the polarity of a mammary acinus and induce a partially transformed state that resembles the differentiated, premalignant stage of human breast cancer, carcinoma in situ. Activation ErbB 1 homodimers was unable to affect the acinar structures suggesting that ErbB 1 and ErbB2 homodimers differ in their ability to affect polarity of a mammary acinus. I believe that this approach can be used to analyze the effects of candidate oncogenes in polarized epithelial structures may provide us insights into the biological activities involved in early stages of carcinogenesis.
5a:
Characterization of cells expressing ErbB chimeras. To generate stable cell lines expressing synthetic ligand-inducible ErbB 1 or ErbB2 receptors, MCF1OA cells were infected with retroviruses encoding chimeric-ErbB receptors (p75.B 1 and p75.B2, Fig. IA) consisting of the extracellular and transmembrane domains of the p75 low-affinity NGF receptor and the ErbB cytoplasmic domain linked to the synthetic ligand binding domain, FKBP. The chimeric ErbB receptors can be dimerized using the bivalent FKBP ligand, AP1510 ( Figure 1A ) (1) . Cell lines expressing comparable levels of p75.B11 and p75.B2 (Fig 1B iii) were selected for further analyses. Treatment with API5 10 induced tyrosine phosphorylation of both p75.B 1 and p75.B2 receptor chimeras (Fig. 1B i, ii, lanes 1-6 and 9-14) but did not alter the phosphorylation status of endogenous ErbB 1, 2 or 3 ( Fig. 1B i lanes 1-6 and data not shown). Conversely, stimulation with EGF activated the endogenous EGF receptors but did not result in activation of the chimeric receptors (Fig 1  B i lanes 7,8 and 15,16 ). Thus, synthetic dimerizing ligands can be used to activate the chimeric ErbB receptors without interfering with endogenous receptors and vice versa.
In order to determine whether activation of p75.B 1 and p75.B2 homodimers can result in activation of downstream signaling pathways in this cell system, we analyzed the activation of a downstream effector molecule Erk2. As observed in Ratl fibroblasts (1), homodimerization and activation of either p75.B 1 or p75.B2 resulted in a 5-7 fold increase in Erk2 kinase activity (Fig. IC) suggesting that both homodimers were equally competent to initiate the signaling cascade required for activation of Erk2. The Erk2 kinase activity stimulated by AP1510 was 2-4 fold weaker than that stimulated by 8 nM EGF (Fig. 1C compare lanes 2,3 with 4 and 6,7 with 8).
To evaluate whether dimerization of chimeric ErbB receptors can stimulate a biological outcome we evaluated the ability of ErbB homodimers to induce proliferation in the absence of EGF. Like the parental MCF-1OA cells, neither the p75.B 1 nor the p75.B2 expressing cells were able to proliferate in the absence of exogenous EGF (Fig 2A) . The basal proliferation observed in the absence of EGF was likely due to the presence of 2% serum and insulin in the media ( Fig. 2A) . Activation of either p75.B1 or p75.B2 homodimers was sufficient to stimulate EGF-independent proliferation however; p75.B2 homodimers were significantly more potent than p75.B1 homodimers (Fig 2A) . These results suggest that dimerization of p75.B 1 or p75.32 chimeras was sufficient to stimulate a biological outcome.
In order to determine whether activation of p75.B1 or p75.B2 homodimers induced morphological alterations in MCF-10A cells, we monitored the morphology of cells grown in the presence of AP15 10 and examined f their ability to grow in soft agar. Activation of p75.B1 or p75.B2 homodimers did not lead to induction of a transformed morphology or growth in soft agar (see below) suggesting that activation of p75.B 1 or p75.B2 homodimers, at the given levels of expression, was not sufficient to induce morphological transformation of normal MEC.
Acinar structures were generated by plating MCF-1 OA as a single cell suspension in matrigel. After 10-12 days in culture, each cell formed an acinus containing 20-30 cells (Fig 2B i, ii) . Confocal analyses of DAPI labeled acini revealed that the acinar units had basally localized nuclei and a hollow lumen (Fig 2Biii) . Immunostaining for basal surface markers (Coll IV (Fig 2Di) , (c6 integrin (data not shown)), and cell-cell junction markers (13-catenin (Fig 2D ii) , E-cadherin (data not shown) suggests that the acinar structures consist of polarized epithelial cells. We did not observe any change in the size of the acini between day 8 and 21 suggesting that they have reached a growth arrested/differentiated state. To establish the time at which the acinar structures became growth arrested, acini were trypsinized and cell number was determined at regular intervals (Fig 2C) . In the absence of synthetic ligand, cells expressing ErbB chimeras proliferated and growth arrested between days 4-6, similar to the parental MCF-10A cells (Fig 2C) . In order to determine whether each acinar unit was derived from a single cell, we labeled cells with a lipophillic dye, DiI, and diluted them with unlabelled cells during the morphogenesis assay. When we followed a DiI labeled cell throughout the period of the assay we were able to conclude that each acinus was clonally derived from a single cell (data not shown). Taken together these results suggest that MCF-10A cells expressing the chimeric ErbB receptors can be used to generate acinar structures that resemble the mammary acini in an adult breast.
5b:
Activation of ErbB receptors in polarized acinar structures: In order to evaluate the effect of acute activation of ErbB receptors in polarized acini, we allowed p75.B1 or p75.B2 expressing cells to form growth arrested acinar units consisting of polarized epithelial cells. On day 10 or 12, the EGF containing medium was replaced with AP1510 containing media and the assay was continued for an additional 8-10 days. Activation of p75.B 1 homodimers did not induce significant changes in acinar structures (Fig. 3A compare ii with iv). Confocal analyses of DAPI labeled structures suggested that the acinar structures retained a hollow lumen in the presence of AP15 10 ( Fig. 3A v) .
Activation of p75.B2 however, resulted in dramatic changes in the acinar structures ( Figure 3B compare i, iv). Confocal analyses showed that acini maintained in the absence of AP1510 remained growth-arrested and retained a polarized acinar organization ( Fig. 3B  iii) ; whereas acini maintained in the presence of AP1510 lost their polarized organization and developed structures consisting of multiple of acinar units with filled lumen (Fig. 3B  v) . These multiple acinar units were fused at the base of each structure as revealed by comparing two serial cross sections of a single structure along the 'z' axis (compare Fig.  3B v and 3B vi). Upon activation of p75.B2, more than 70% of the acini lost their polarized acinar organization (filled lumen) and about 35% of the acini formed the multiacinar structures. Most of the multi-acinar structures were at least 10 fold larger (average size: 1mm 2 ) than normal acini (average size: 0. 1mm 2 ) while some of the structures were 100 fold larger than a normal acini (Fig 3B) . In order to determine whether a single acinus can give rise to these unorganized multi-acinar structures, DiI labeled acini were monitored. The results indicate that a single acinus can indeed give raise to the multi-acinar structures (data not shown).
In order to determine whether the multi-acinar structures have acquired heritable genetic changes, we isolated a single multi-acinar structure, expanded the cells under normal culture conditions and subjected them to another round of experimentation. When plated on matrigel in the absence of synthetic ligand these cells formed polarized acinar structures like the parental cells suggesting that they were still dependent on activation of ErbB2 (data not shown). Stimulation of these structures with AP 1510 resulted in the same frequency of multi-acinar structures suggesting that they have not acquired any heritable genetic change and there may be epigenetic factors that play a role in formation of p75.B2-induced multi-acinar structures (data not shown).
In order to better understand the organization of the multi-acinar structures we immunostained with markers for polarized epithelial cells. The cells at the periphery of the filled acini that make up the multi-acinar structure, had basally localized ca6 (Fig. 4 c,e (see arrows)) and P34 (data not shown) integrins, P3-catenin (Fig 4 f) , and E-cadherin (data not shown) at cell-cell junctions; and basally deposited collagen IV (Fig. 4 d) . However, the cells in the middle of a filled acini had no polarized distribution (Fig 4 e ,f see the cell with asterisk) suggesting that the filling of the luminal space was accompanied by loss of acinar polarity. The multi-acinar structures had a high percentage of cells expressing the proliferating nuclear marker Ki-67 (Fig. 4 h) whereas the acinar units that were not stimulated with AP1510 and maintained in the presence of EGF had no ki-67 positive cells (Fig 4 g ) confirming that activation of p75.B2 reinitiates cell cycle progression in growth arrested acinar units.
Taken together these observations suggest that activation of p75.B2, but not p75.B 1, reinitiates proliferation within growth arrested acini and disrupts the polarized organization of an acinus while retaining epithelial properties.
5c:
ErbB2 homodimers do not confer migratory or invasive properties: Transition from benign to invasive cancer is thought to correlate with acquisition of migratory and invasive properties. In order to determine whether activation of p75.B2 homodimer induced properties of invasive cancer, we performed invasion assays using matrigel coated transwell chambers. Unlike the invasive tumor-derived cell line, MDA-MB-231, MCF10-A cells expressing p75.B2 did not show any invasive potential whether stimulated with AP15 10 or with EGF (data not shown). Consistent with these results, when MDA-MB-231 cells were grown in matrigel they displayed numerous invasive protrusions ( Figure 5A ) while no such processes were observed in the p75.B2 induced MCF-10A structures ( Figure 5B ). In addition, activation of p75.B2 homodimers did not induce EGF-independent migration in a uncoated transwell assay ( Figure 5C ) whereas, as shown previously (), EGF was able to stimulate migration under the same conditions. These observations suggest that activation of ErbB2 alone is not sufficient to stimulate migration or invasion of normal MEC.
5d:
Extracellular matrix and 11 integrins are required for ErbB2 induced morphogenesis:
In order to determine whether the ability of ErbB2 to induce multi-acinar structures correlated with its ability to induce transformation, we plated ErbB2 expressing MCF-1OA cells in soft agar either in the presence or absence of AP1510. Activation of ErbB2 was not sufficient to stimulate colony formation in soft agar (Fig 6 a,b) . However, the ErbB2 chimera retains its capacity to induce anchorage independent growth in other cell types as demonstrated by the ability of Ratl fibroblasts expressing the same chimera to form colonies in a ligand-dependent manner (Fig 6 c, d ). Since the MCF-10A cells and the Ratl fibroblasts express similar levels of the ErbB2 chimera the variation in colony forming ability is not due to differences in levels of expression. These results suggest that the ability of ErbB2 to induce multi-acinar structures does not require full transformation involving anchorage-independent growth of MEC.
Several studies have shown that normal MEC require functional P31 integrins for proliferation, survival and morphogenesis (2, 3) and that cancer derived cell lines can by pass this requirement for proliferation and morphogenesis (2) . In order to determine whether activation of p75.B2 can by pass the requirement for 131 integrins, we grew p75.B2 expressing cells in the presence of 131 integrin function blocking antibodies. Blocking 131 integrins inhibited the ability of p75.B2 to induce morphogenesis in matrigel (Fig 6 e, f) . These results suggest: (1) p75.B2 activation is not sufficient to rescue the 131 integrin requirement of MEC, and (2) ErbB2 cooperates with 131 integrins to stimulate morphogenesis of epithelial cells in matrigel.
Discussion:
Here we report that activation of ErbB2 in preformed, growth-arrested, mammary epithelial acini results in re-initiation of proliferation, loss of polarized organization and formation of structures containing multiple acinar units. Each acinus within these structures had a filled lumen and was surrounded by an intact basement membrane, and displayed no invasive properties and was still dependent on signals from 131 integrin for proliferation. Thus, ErbB2 dimerization in preformed acini induces a partial transformed phenotype and the ErbB2-induced structures resemble a premalignant stage of breast cancer in vivo referred to as carcinoma in situ. Interestingly, activation of ErbB 1 homodimers was not able to either reinitiate growth or alter the polarity of a preformed mammary epithelial acinus.
Our results show for the first time that ErbB 1 and ErbB2 homodimers differ in their ability to affect the polarity of mammary acini. It is not clear whether the ErbB2-induced disruption of polarized mammary acini results from events that reinitiate proliferation of growth-arrested epithelial cells or whether additional events are required to alter the polarity of the acinar epithelial cells. It is likely that the ability of ErbB receptors to stimulate proliferation is not sufficient to induce disruption of the polarized acinar structures because, both ErbB 1 and Erb2 homodimers retain the ability to activate MAPK and stimulate proliferation of MEC and fibroblasts in 2D ( Figure IC, 2A and ((1)) ) and previous studies in other cell types have shown that both ErbB 1 and ErbB2 homodimers can stimulate proliferation (4, 5, 6) . In addition, the possibility that a signal to proliferate is not sufficient to disrupt the polarized organization of an epithelial acinus is further supported by findings that expression of myc or the E7 gene from papilloma virus deregulate proliferation of epithelial cells without disruption of polarity (7, 8) . Thus, the differential ability of ErbB receptors to perturb mammary acini may reflect differences in their potential to alter the polarity of epithelial cells. Consistent with this possibility, preliminary results suggests that activation of ErbB2 disrupts the localization of ZO-1, a protein known to localize to the tight junctions in polarized epithelial cells (data not shown). Recent studies have shown that proteins that control epithelial cell polarity such as scribble, discs large and lethal giant larvae act as tumor suppressors in Drosophila (9) suggesting that regulation of cell architecture may play an important role in growth control (10) . Consistent with this possibility, overexpression of active versions of Rac, Rho (11), fos (8) and jun (12) have been shown to affect polarity of epithelial cells in culture. It will be of interest to determine whether ErbB receptors differentially regulate proteins that control epithelial cell polarity.
ErbB2 has been shown to play an important role in migration and invasion (13) . The data presented here suggests that ErbB2 homodimers are not sufficient to stimulate migration or invasion of normal MECs. Our results are consistent with previous the * S observations that activation of ErbB2 homodimers is not sufficient to stimulate formation of lamellipodia-like structures or morphological changes in 32D hematopoietic cells and HB2 MEC respectively (14, 15) . In addition, the evidence that the highest frequency (80-85%) of ErbB2 amplification is detected in comedo DCIS tumors which are non-invasive, premalignant mammary tumors supports the concept that ErbB2 dimerization is not sufficient to induce invasive growth of tumor cells (16) . It is possible that ErbB2 expressing tumors may require additional genetic/epigenetic events or may need to attain higher levels of ErbB2 expression to gain invasive properties. Recent studies have shown that activation of Rac, Cdc42 or PI3'K can induce invasion and migration of MECs (17) . Another possible cooperating oncogene in breast tumors is ErbB3, another member of the ErbB receptor family (18) . ErbB3 is highly overexpressed in 100% of ErbB2-induced mouse mammary tumors (19) and 63-67% of human tumors overexpressing ErbB2 are also strongly positive for ErbB3 (20) . Lastly, the cell-cell adhesion molecule E-cadherin is thought to negatively regulate epithelial migration/invasion (21) . Although it was shown that expression of active ErbB2 results in suppression of E-cadherin gene expression (22) we fail to see such a coordinate regulation in our experiments (data not shown).
Our results suggest that activation of ErbB2 homodimers in normal MEC does not induce the full spectrum of phenotypic changes commonly associated with oncogenic transformation. These results are consistent with some previous studies (23, 24, 25) while they contrast with others (26, 27, 28, 29) . For example, MTSV1-7 human MECs transfected with ErbB2 form colonies in soft agar and tumors in nude mice (26) , while MCF-10A cells transfected with ErbB2 have weak colony forming efficiency and do not form tumors in nude mice (25) . It is not possible to directly compare our results with previous observations since earlier studies were not designed to activate ErbB homodimers without contributions from endogenous ErbB receptors and the isolation of stable, noninducible transfectants involve selection of the most overt altered phenotypes. One other study examined the effect ErbB2 dimerization on morphogenesis using EPH4 mammary epithelial cells expressing a Trk-ErbB2 chimeric receptor that was dimerized with NGF (30) . The activated ErbB2 chimera was able to induce normal morphogenesis with no reported perturbations in acinar structures. It is possible that the levels of expression of this receptor were below the threshold required for loss of polarity. Our studies were performed under conditions where ErbB2 was inducibly activated in preformed, growtharrested, polarized structures to mimic the conditions in which ErbB2 is amplified and activated in vivo.
Although activation of ErbB2 was not sufficient to induce anchorage-independent growth, it was sufficient to induce a partially transformed state that resembles the differentiated, premalignant stage of human breast cancer, CIS. In CIS, the lumen of mammary ducts or lobules are filled with proliferating cells without any invasion into the surrounding stroma (31) . Since one class of DCIS (comedo) shows extremely high levels of ErbB2 amplification, it is possible that ErbB2 amplification in vivo induces a state similar to that observed in our cultured mammary acini. A related approach where Fos-ER and Jun-ER fusion proteins were activated in tubular structures composed of mammary epithelial cells demonstrated that activation of these protooncogenes results in a more dramatic phenotype involving not only loss of polarized organization but also induce an epithelial-mesenchymal conversion (8, 12) . These studies together with ours suggest that analyzing the effects of candidate oncogenes in polarized epithelial structures may provide us insights into the biological activities involved in early stages of carcinogenesis.
In summary, these studies provide evidence which demonstrate that ErbB 1 and ErbB2 receptors have differential abilities to alter the polarity of a growth arrested three dimensional acinus and also demonstrate that acute activation of ErbB2 results in generation of a multi-acinar structures that closely mimic carcinoma in situ in vivo. We also show that growth arrested acinar structures can be used to study the early events of oncogenesis in culture. 
6:

8: Conclusions:
I have combined the synthetic ligand inducible dimerization strategy and the 3D cell culture approach to study the mechanisms by which ErbB family of receptors regulate MEC biology. My studies thus far have shown that synthetic ligands can be effectively used as an alternative to natural ligands to study biological and biochemical difference between distinct ErbB dimers. The use of 3D culture conditions has enabled me to study the early events that occur during carcinoma initiation in an adult breast. The results presented here suggests that activation of ErbB2 within a normal acinus results in loss of acinar polarity as observed by the filling of luminal space with proliferating cells. Loss of epithelial polarity is thought to be an early event in carcinoma initiation. I believe that the combination of controlled ErbB activation and the 3D culture conditions would allow me to understand the mechanisms by which ErbB receptors regulate acinar polarity. My results also show that ErbB 1 and ErbB2 receptors differ in their ability to regulate acinar polarity, it is possible that understanding the mechanisms by which ErbB receptors differentially control epithelial polarity may shed light on novel mechanisms involved in carcinoma initiation. These studies may prove to be valuable areas of therapeutic intervention. The four members of the ErbB family of receptor tyrosine kinases are involved in a complex array of combinatorial interactions involving homo-and heterodimers. Since most cell types express more than one member of the ErbB family, it is difficult to distinguish the biological activities of different homo-and heterodimers. Here we describe a method for inducing homo-or heterodimerization of ErbB receptors by using synthetic ligands without interference from the endogenous receptors. ErbB receptor chimeras containing synthetic ligand binding domains (FK506-binding protein [FKBP] or FKBP-rapamycin-binding domain [FRB] ) were homodimerized with the bivalent FKBP ligand AP1510 and heterodimerized with the bifunctional FKBP.FRB ligand rapamycin. AP1510 treatment induced tyrosine phosphorylation of ErbB1 and ErbB2 homodimers and recruitment of Src homology 2 domain-containing proteins (Shc and Grb2). In addition, ErbB1 and ErbB2 homodimers activated downstream signaling pathways leading to Erk2 and Akt phosphorylation. However, only ErbB1 homodimers were internalized upon AP1510 stimulation, and only ErbB1 homodimers were able to associate with and induce phosphorylation of c-Cbl. Cells expressing AP1510-induced ErbBl homodimers were able to associate with and induce phosphorylation of c-Cbl. Cells expressing AP1510-induced ErbB1 homodimers were able to form foci; however, cells expressing ErbB2 homodimers displayed a five-to sevenfold higher focus-forming ability. Using rapamycin-inducible heterodimerization we show that c-Cbl is unable to associate with ErbB1 in a ErbB1-ErbB2 heterodimer most likely because ErbB2 is unable to phosphorylate the c-Cbl binding site on ErbBl. Thus, we demonstrate that ErbBl and ErbB2 homodimers differ in their abilities to transform fibroblasts and provide evidence for differential signaling by ErbB homodimers and heterodimers. These observations also validate the use of synthetic ligands to study the signaling and biological specificity of selected ErbB dimers in any cell type.
ErbB family receptor tyrosine kinases (RTKs) ErbBl (also ErbB family members partake in a complex process of latknown as human epidermal growth factor [EGF] receptor 1 eral signaling (also referred to as combinatorial interactions) [HER1] or EGF receptor [EGFR]), ErbB2 (also known as by forming ligand-induced heterodimers between different HER2 or Neu), ErbB3, and ErbB4 consist of an extracellular family members (1, 18, 55) . It is likely that heterodimerization ligand-binding domain, a single transmembrane domain, an is mediated by ligand bivalency (71). Each ligand has been uninterrupted tyrosine kinase domain, and a cytoplasmic tail.
shown to favor certain dimeric combinations over others, sugThe ErbB family members play important roles during the gesting that in cells expressing all four ErbB receptors a given growth and development of a number of organs including the ligand induces a hierarchical order of ErbB receptor dimerizaheart (9, 17), the mammary gland (9, 27, 77) , and the central tion (72) . Among the ErbB RTKs, ErbB2-containing heteronervous system (9, 17, 28) . In addition, ErbB overexpression dimers are preferred over other ErbB homo-or heterodimers, is associated with tumorigenesis of the breast, ovaries, brain, suggesting that ErbB2 plays a central role in both ligand bindand prostate gland (1, 9, 36) . Experiments in transgenic mice ing and signal transduction (4, 29, 37, 52, 62, 73) . EGF stimand cell culture models clearly indicate that ErbB receptors ulation of cells engineered to lack surface expression of ErbB1 and their ligands can promote the development and progresresults in defective ErbB2 phosphorylation, and EGF or sion of mammary tumorigenesis (36, 74).
NRG1 stimulation of cells engineered to lack surface expresThere are at least 16 different EGF family ligands that bind sion of ErbB2 results in impaired ErbBl, ErbB3, and ErbB4 ErbB receptors (55) . The ligands can be grouped into three phosphorylation (30) . Taken together, these observations highcategories: (i) those that bind to ErbB1 alone (EGF, translight the importance of combinatorial interactions in ErbB forming growth factor ct, and amphiregulin), (ii) those that receptor signaling. Although ErbB2 is recruited into many bind to ErbB3 and ErbB4 (neuregulin 1 [NRG1] and NRG2), heterodimers it is likely that different heterodimers have disand (iii) those that bind to ErbB1 and ErbB4 (betacellulin, tinct signaling specificities. The evidence that different ligands heparin-binding EGF, NRG3, and epiregulin) (32, 55) . The induce distinct phosphorylation patterns on ErbB1 and ErbB2 binding of an EGF family ligand to its cognate receptor results is consistent with this possibility (19a, 51) . in the dimerization and activation of the receptor (76) . immunoblotted for 1.5 to 3.0 h with either anti-pTyr (PY20-HRP; Transduction Labs; 1:3,000), anti-EGFR (1:1,000; Transduction Labs), anti-Erk2 (1:1,000; DNA constructs. The expression vectors for the ErbB chimeras were conUpstate Biotechnology Inc.) antiphospho-473 Akt (1:1,000; New England Biostructed as follows: the extracellular and transmembrane domains of low-affinity labs), anti-Akt (1:1,000; New England Biolabs), anti-Flag (1:1,000; M2; BabCo), nerve growth factor receptor (p75) was PCR amplified as an EcoRI/BamlHI anti-Shc (1:1,000; Transduction Labs), anti-Grb2 (1:1,000; Transduction Labs), fragment and subcloned into the retroviral expression vector SRuMSVTKNeo or anti-betal integrin (1:1,000) antibodies. The immunoblots were washed five to (kindly provided by 0. Witte). To generate the EcoRI/BamHI fragment, the 5' seven times, incubated with appropriate horseradish peroxidase-conjugated secprimer was engineered to have an EcoRI site and the 3' primer was engineered ondary antibody subsequently, washed five to seven times, reacted with enhanced to have in-frame Spet and Xbat sites followed by either a hemagglutinin (HA) or chemiluminescence (NEN), and subjected to autoradiography. For stripping the Flag epitope tag, stop codons, and BainHI restriction site. The resulting vectors blots were incubated in a strip buffer (62.5 mM Tris. CI [pH 6.8], 2% SDS, 0.7% were referred to as either p75.HA or p75.Flag. The ligand-binding domains mercaptoethanol) at 50'C for 30 min.
FK506-binding protein (FKBP [one or two copies]) and FKBP-rapamycin-bind-
Receptor internalization experiments were carried out as follows: cells were ing domain (FRB) of FKBP-rapamycin-associated protein (FRAP) (57) were stimulated with AP1510 or the ethanol alone for the indicated lengths of time. subcloned as XbaI/SpeI fragments into p75.HA and p75.Flag to generate
The cells were rinsed three times with ice-cold PBS (pH 8.0) and incubated with p75.F1.HA (Fl, one copy of FKBP) or p75.F2.HA (F2, two copies of FKBP) or PBS containing 0.5 mg of NHS-S-S-Biotin (Pierce) at 4°C for 1 h. The cells were p75.R1.Flag (RI, one copy of FRB domain) (Fig. 1B) . The intracellular domains subsequently rinsed three times with ice-cold PBS and lysed in Ix modified of ErbB1 (B1) and ErbB2 (B2) were obtained by PCR with Pfii DNA polymerase radioimmunoprecipitation assay buffer (150 mM NaCI, 20 mM Tris t HCI [pH (Stratagene). The primers were designed such that they contain in-frame XbaI 7.5], 0.1% SDS, 1.0% sodium deoxycholate, 1.0% Triton X-100, 2 jig of aprotinin and Spet restriction sites in the 5' and 3' ends, respectively. ErbB1 was amplified per ml, and 2 tig of leupeptin per ml). Equal amounts of lysates (300 [Lg) were with the primers 5' GCGATCTCTAGACGAAGGCGGCCACATCGTTC incubated with 75 pl 1 of Sepharose beads coupled to NeutrAvidin (Pierce) on a GG and 5' GCATCGACTAGTTGCTCCAATAAATTCACTGCTTTG with rotating platform for 1 to 1.5 h. The immunoprecipitates were washed three a T47D cDNA library (generated by random priming poly[A]-selected mRNA).
times with modified radioimmunoprecipitation assay buffer and resuspended in The kinase-dead ErbB1 (kdB1) was amplified with the Met721Ala mutant hu-1× sample buffer. man ErbBl cDNA (kindly provided by Alan Wells). Both ErbB1 and kdB1 PCR Cell cycle analysis. Parental Ratl cells or p75.BI.F1.HA (clone 9), p75.B1.F2.HA fragments were subcloned into a shuttle vector digested with Xbat and SpeI (clone 6), or p75.B2.F2.HA (clone 4) were plated at a density of 8 X 10' cells per restriction enzymes. The ErbB2 cytoplasmic domain was amplified as two fragwell in a six-well plate. After 48 h the cells were switched to serum-free media for ments from a rat Neu cDNA (kindly provided by William J. Muller), making use 24 h and subsequently stimulated with indicated amounts of AP1510 or 10 ng of of an internal unique Ncol site. The 5' fragment was amplified with primers EGF per ml for 18 to 20 h. Cells were trypsinized, resuspended in 1.0 ml of 10% 5' GCGATCTCTAGAAAACGAAGGAGACAGAAGATCC and 5' GGAG serum-containing medium, and transferred to a tube containing 10.0 ml of lX GTCGGGGTACCTGTCATGG. The 3' fragment was amplified with primers PBS. The cells were pelleted by centrifugation at 3,000 X g for 4 min. Pellets were 5' CCATCCAGCCCCATGGACAGTACC and 5' GCATCGACTAGTTACA washed again with 10.0 ml of l X PBS and then resuspended in 0.5 ml of 1 X PBS.
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A B (Fig. 1A) and can induce the homodimerization of proing different concentrations of AP1510. Cells from one infected well were plated teins fused to FKBP. To induce heterodimerization, we used onto 10-cm-diameter plates in media containing 500 ixg of G418 per ml for 10 to the natural product rapamycin, which binds to one copy of 12 days. The focus assay was carried out for 14 days by changing the drugcontaining media once every 3 days. The plates were fixed with 4% formalin and FKBP and one copy of the FRB domain of FRAP (Fig. 1A) .
stained with 4% Giemsa. Previous experiments have shown that AP1510 is active To create dimerizable ErbB receptors, the FKBP or FRB for at least 4 days as dilute aqueous solutions at 37°C (data not shown). For domain and an epitope tag were fused to the C-terminal end of another experiment (see Fig. 7 ), Rati cells were plated at 3 x 10' cells per 10-cm-diameter plate and infected with a larger amount of virus stock and the the ErbB cytoplasmic domain (Fig. 1C) . To prevent the bindexact number of CFU per plate was estimated by trypsinizing and plating one ing of EGF family ligands released by autocrine secretion, the infected plate under 750 pRg of G418 per ml. extracellular and transmembrane domains of the low-affinity NGF receptor p75 were substituted for the analogous domains RESULTS of ErbBl1 and ErbB2. Using FKBP-or FRB-containing ErbB Synthetic ligand-mediated ErbB dimerization. To study the receptor chimeras it is possible to generate homodimers with signaling and biological specificities of different ErbB dimers, AP1510 or heterodimers with rapamycin (Fig. 1D) . Fig. 1A; compare lanes 198-2 to 6 and 9). Similar results were obtained in three independent Ratl clones expressing p75.B1.F1.HA (data not shown).
.
• <-EGFR AP1510 stimulation of the parental Rat1 fibroblasts did not <_ p75.Bl.F, have any effect on the tyrosine phosphorylation of cellular proteins (data not shown). To specifically examine the tyrosine * phosphorylation status of the chimeric receptor, anti-HA im-75 -munoprecipitates were immunoblotted with anti-pTyr antibodies. The p75.B1.F1 chimera was inducibly tyrosine phosphorff ylated with maximal stimulation at 500 nM AP1510 (Fig. 2B , • * lanes 1 to 6). As expected, neither the monomeric ligand nor EGF induced tyrosine phosphorylation of the ErbB1 chimera 49- ].Shc (Fig. 2B, lanes 7 to 9) . Synthetic ligand-mediated activation of the p75.Bl.F1.HA receptor did not show any increase in tyrosine phosphorylation levels of the endogenous ErbB2 receptor (data not shown). Thus, the activation of the chimeric receptor appears to be independent of both EGF ligands Synthetic ligands activate other members of the ErbB family, and the activated receptors retain their kinase specificity. In order to examine whether dimerization of cytoplasmic doDimerization of ErbB1 cytoplasmic domain with synthetic mains can activate other ErbB family members and whethligands results in a dose-dependent stimulation of receptor er synthetic ligand-activated ErbB kinases retain their kinase and substrate phosphorylation. To establish whether synthetic specificity, we derived Ratl-based stable cell lines expressing ligands can be used to dimerize ErbB receptors, we examined AP1510-inducible ErbB2 chimeras. We found that cell lines exthe dimerization and activation of the ErbB1 cytoplasmic pressing ErbB2 chimeras with one copy of FKBP (p75.B2.F1.HA) domain (B1) fused to one copy of FKBP (F1) (denoted as had very high levels of basal tyrosine phosphorylation (data not p75.B1.F1.HA) (Fig. IC) . Stable cell lines expressing the shown); however, cells expressing p75.B2.F2.HA, which conp75.B1.F1,HA chimera were derived by using Ratl fibroblasts.
tains two copies of FKBP (F2), had low levels of basal tyrosine AP1510, but not FKS06, treatment resulted in a dose-depenphosphorylation and showed AP1510-inducible phosphorydent increase in tyrosine phosphorylation of cellular proteins lation. To make an objective comparison between ErbBl ( Fig. 2A; compare lanes 1 to 6 and 7 to 8). As expected, the and ErbB2 homodimers, we derived cell lines expressing two cells were still sensitive to EGF stimulation (Fig. 2A, lane 9) .
FKBP variants of either ErbB1 or ErbB2 (p75.B1.F2.HA or Interestingly, the pattern of tyrosine phosphorylation after p75.B2.F2.HA). As observed with cells expressing the single AP1510 stimulation was comparable to the pattern obtained FKBP ErbB1 chimera (p75.B1.F1.HA), addition of synthetic after EGF stimulation ( Fig. 2; compare lanes 6 and 9) (p75.B1.F2.HA) resulted in increased phosphorylation of the chimeric receptor and selected proteins (Fig. 4A, lanes 1 to 3) .
AP1510 stimulation also resulted in tyrosine phosphorylation a 2 3 4 5 6 7 8 of the ErbB2 chimera, p75.B2.F2.HA, and other protein sub-IP: anti-Cbl Blob anti-pTyr strates (Fig. 4A, lanes 5 to 7) .
In order to examine whether downstream signaling pathways are activated by the ErbB2 chimera, we examined the activa- of Erk2 (Fig. 4C) . To examine activation of Akt, total cell lycells stimulated with AP1510 (nanomolar) or EGF (50 ng/ml) were resolved sates were immunoblotted with anti-Akt antibodies that spe- promote cell cycle progression. ErbB1 and ErbB2 homodimers differ in their abilities to induce focus formation in Ratl fibroblasts. Since ErbB family ylation (Fig. 4D) , whereas phosphorylation of c-Cbl was barely members are known to be potent oncogenes, we examined detectable following ErbB2 homodimerization. This differwhether ErbB1 or ErbB2 homodimers can induce focus ential phosphorylation of c-Cbl was also observed in COS7 cells transiently transfected with either p75.B1.F2.HA or p75.B2.F2.HA chimeras (data not shown). These observations suggest that dimerization of ErbB receptors activated by synthetic ligands can retain their kinase-specific functions as de-2.5-termined by their ability to phosphorylate c-Cbl. lysates were then subjected to precipitation with NeutrAvidincoupled beads, and the bound proteins were immunoblotted with HA tag antibodies to determine the amount of chimeric 1 receptor present at the cell surface. AP1510 treatment of T ErbBl-expressing (Fig. 5A, lanes 5 to 7) but not ErbB2-ex-1T pressing (Fig. 5A, lanes 12 to 14) ErbB1 chimera (Fig. 5A, lanes 1 to 4) (Fig. 7 and Table 1 ). In concopies of FKBP (p75.B2.F2.HA) (see Materials and Methods) trast, the expression of ErbB1 chimera fused to two FKBP were grown in the presence of AP1510 for 48 h, and the (p75.B1.F2.HA) showed weak focus-forming activity (Fig. 7) , changes in morphology were recorded (Fig. 8) . Cells expresswith only 10% of the infected cells forming foci (Table 1) . In ing p75.B1.F2.FIA (Fig. 8g to i) or p75.B2.F2.HA (Fig. 8m to addition, the foci induced by the ErbB1 chimera had a diffuse o), but not cells expressing p75.F1.HA (a p75 chimera without morphology and showed faint Giemsa staining relative to the dense, intensely stained foci induced by the ErbB2 chimera (Fig. 7) . The expression of a ErbB2 chimera with one copy of APi510 stimulation (Fig. 9C , lanes i to 3 and 7 to 9), likely due 8d to f).
to the inability of AP151O to bind FRB-fused chimeras. After trypsinization and replating of the AP1510-treated However, rapamycin stimulation resulted in tyrosine cells in media without the ligand, the cells reverted to a nonphosphorylation of the kinase-dead ErbBl-FRB chimera transformed state, displaying a well-spread morphology and (p75.kdBl.R1.Flag) (Fig. 9C , lanes 4 to 6 and 10 to 12) by both contact inhibition (Fig. 8j and p) . This observation suggests kinase-active ErbB1-FKBP (lanes 4 to 6) and kinase-active that the morphological changes require the continuous presErbB2-FKBP (lanes 10 to 12). Since rapamycin is known to ence of the dimerizing ligand.
dimerize an FKBP domain and an FRB domain ( Fig. 1) , this Synthetic ligand-induced heterodimerization between ErbB observation suggests that rapamycin can induce heterodimers receptors. It has not been possible to study the signaling specbetween the kinase-dead ErbBl-FRB and kinase-active ErbBificities of different FrbB heterodimers in isolation, since most FKBP receptors. Rapamycin stimulation did not change the cell types express more than one ErbB family member. In orphosphorylation status of either kinase-active ErbBl-FKBP der to establish whether synthetic ligands can be used to form (Fig. 9B , lanes 4 to 6) or kinase-active ErbB2-FKBP (Fig. 9B , heterodimers of selected ErbB receptors, we generated a chilanes 10 to 12), possibly because the dimer comprises one mera containing the kinase-dead variant of erbB1 (kdB1) fused kinase-active and one kinase-dead receptor. This is consistent to the FRB domain and a Flag epitope tag (p75.kdBl.R1.Flag; with the notion that the tyrosine phosphorylation of ErbB see Materials and Methods). The p75.kdBl.R1.Flag chimera receptors occurs primarily by frans-phosphorylation within a was not phosphorylated on tyrosine when expressed trandimer (76) . The kinase-active receptors observed in the antisiently in C0S7 cells (data not shown). Stable pools of Rati Flag immunoprecipitates from rapamycin-stimulated cell lycells coexpressing the kinase-dead ErbBl-FRB chimera sates (Fig. 9C, lanes 4 to 6 and lanes 10 to 12) were due to the (p75.kdBl.R1.Flag) and either the wild-type ErbBl-FKBP ability of rapamycin to induce a stable heterodimeric complex chimera (p75.B1.F2.HA) or the wild-type ErbB2-FKBP chibetween the Flag-tagged kinase-dead and weakly phosphorymera (p75.B2.F2.HA) were generated (Fig. 9A) . As illustrated lated kinase-active ErbB receptors (Fig. 9B, lanes 1 and 7) . in rapamycin can be used to form heterodimers in the absence of dimer). The kinase-dead ErbB1 receptor fused to the FRB homodimers and AP1510 can be used to form homodimers in domain (p75.kdB1.R1.Flag) was cotransfected with either kithe absence of heterodimers.
nase-active ErbBl-FKBP chimera (p75.Bl.F2.HA) or kinasec-Cbl can differentiate ErbBl in homodimers from ErbB1 in active ErbB2-FKBP chimera (p75.B2.F2.HA) in COS7 cells. In ErbBl-ErbB2 heterodimers. It is possible that heterodimers the presence of rapamycin the kinase-active FKBP-fused have different signaling specificities than homodimers. We testErbB1 and ErbB2 receptors coimmunoprecipitate with the ed whether the kinase-dead ErbB1 receptor, phosphorylated kinase-dead ErbB1-FRB.Flag chimera ( Fig. 9 and 10 ). Rapaby either a kinase-active ErbB1 (homodimer) or a kinasemycin stimulation resulted in increased phosphorylation of the active ErbB2 (heterodimer), differed in its ability to associate kinase-dead ErbBl-FRB chimera (p75.kdBl.R1.Flag) by both with cytoplasmic signaling molecules. Since c-Cbl has been ErbBl-FKBP (p75.B1.F2.HA) (Fig. 10, lanes 1 to 3) and shown to bind selectively to ErbBl1 but not to other ErbB ErbB2-FKBP (p75.B2.F2.HA) (Fig. 10 , lanes 4 to 6) receptors, receptors (41), we asked whether c-Cbl can differentiate bedetermined by anti-Flag immunoprecipitation and anti-pTyr tween the kinase-dead ErbB1 phosphorylated by a kinaseimmunoblotting. Endogenous c-Cbl was also immunoprecipiactive ErbBl receptor (homodimer) from a kinase-dead ErbB1 tated from the same cell lysates, and the precipitates were phosphorylated by a kinase-active ErbB2 receptor (heteroblotted with anti-pTyr antibodies (Fig. 10, lanes 7 to 12) Blot: anti-Cbl identify the ErbB chimeras that bind to c-Cbl. c-Cbl was able play important roles in ligand binding and receptor dimerizato coimmunoprecipitate the tyrosine phosphorylated, kinasetion (11, 12, 14, 59, 60, 66) . The mutation or addition of Cys dead, ErbBI-FRB chimera (p75.kdBl.R1.Flag) only when residues at the juxtamembrane region and generation of unthe kinase-dead ErbB1 was phosphorylated by kinase-active paired Cys residues result in dimerization of ErbB2 (12, 60) . ErbB1 chimera (p75.B1.F2.HA) (Fig. 10, lanes 7 to 9) but not Interestingly, a number of such dimers fail to induce transforwhen kinase-dead ErbB1 was phosphorylated by kinase-active mation, suggesting that forced dimerization is not sufficient for ErbB2 chimera (p75.B2.F2.HA) (Fig. 10, lanes 10 to 12) . a functional activation of ErbB2 (11) . The transmembrane and These observations suggest that c-Cbl can differentiate ErbB1 the juxtamembrane regions of ErbB2 form a helical structure, molecules in a homodimer (p75.B1.F2-p75.kdBl.R1) from and receptor dimerization is thought to promote a helix-helix ErbB1 molecules in a heterodimer with ErbB2 (p75.B2.F2-interaction (12) . It is proposed that some of the Cys modificap75.kdBl.R1).
tion-induced dimerization may result in packing the helices in an unfavorable or nonpermissive orientation for signaling (12) . DISCUSSION Results presented in this report suggest that dimerization of the cytoplasmic domain was sufficient to activate both ErbB1 We demonstrate that synthetic dimerizing ligands can selecand ErbB2 receptors. This is consistent with an earlier report tively activate homo-and heterodimers of the ErbB family of which suggests that membrane localization of the cytoplasmic receptors and result in the activation of signal transduction domain of ErbB2 was sufficient to induce kinase activation and pathways. Synthetic ligand-mediated dimerization and activatransformation (26) . It will be interesting to progressively tion also induce a dose-dependent stimulation of phenotypic change the orientation or location of the synthetic ligandalterations known to be regulated by ErbB receptors (e.g., binding domains within the chimera to ask whether the ErbB stimulation of cell proliferation, morphological transformacytoplasmic domains require a specific dimerization interface. tion, and focus formation). In addition, using a heterodimerSynthetic ligand-inducible dimerization was able to activate izing ligand we demonstrate that c-Cbl can associate with both biochemical and biological processes that are known to be ErbB1 in an ErbBl-ErbB1 homodimer but does not associate stimulated by ErbB receptors. Both ErbB1 and ErbB2 homowith ErbB1 in an ErbBl-ErbB2 heterodimer. These obserdimers were able to induce activation of the serine threonine vations suggest that this approach can be used to study the kinase Akt (Fig. 4) . Akt is a known downstream target of acsignaling and biological specificities of ErbB homodimers and tivated PI 3-kinase. It is unclear how either of these homoheterodimers and provide the first clear evidence for differendimers activates the PI 3-kinase pathway, since neither ErbB1 tial signaling by ErbB homo-and heterodimers.
nor ErbB2 possesses the binding site for the SH2 domain of The extracellular cysteine-rich domains of ErbB receptors p85 subunit of PI 3-kinase (24, 39, 53, 64) . It is possible that * '6L. 19, 1999 HOMO-AND HETERODIMERIZATION OF ErbB RECEPTORS 6855 c-Cbl mediates the ErbBl1 homodimer-induced activation of PI ubiquitinated and downregulated. Such a possibility is consis-3-kinase (63), whereas c-Cbl is unlikely to play a role in ErbB2 tent with the observation that ErbBl1 homodimers are endocyhomodimer-induced activation of the PI 3-kinase pathway tosed (Fig. 5) and degraded, while ErbBl-ErbB2 heterodimers since ErbB2 does not show strong association with c-Cbl (Fig. are recycled to the membrane after EGF stimulation (40). 4 and 8) . Further experiments will be necessary to understand However, the differential association with c-Cbl may also regthe underlying mechanism leading to the activation of PI 3-kiulate multiple downstream signaling pathways that play a role nase by ErbB1 and ErbB2 homodimers.
in signaling by ErbB1 and ErbB2 homo-and heterodimers. The activation of ErbB1 or ErbB2 dimers with synthetic It is unclear why ErbBl1 chimeras with one copy of FKBP ligands resulted in a ligand-dependent acquisition of trans-(p75.B1.F1) did not induce morphological changes or focus formed-cell morphology, while the removal of AP1510 caused formation ( Fig. 7 and 8 ). One copy of FKBP was sufficient to a reversion to a normal morphology. These observations demactivate the receptor since AP1510 induced tyrosine phosphoronstrate the continuous requirement of a dimerization signal ylation of multiple cellular proteins including Erk2 (Fig. 2) , as for maintenance of the transformed morphology. It will be of well as stimulation of DNA synthesis in cells expressing the interest to determine whether the ligand-dependent transforp75.B1.F1.HA chimera (Fig. 6 ). In addition, AP1510 activation mation and reversion can be induced in animal models where of the single FKBP version of the ErbB2 chimera, p75.B2.F1, other mutations are involved during tumorigenesis. The develresults in induction of focus formation ( Fig. 7 and Table 1 ). It opment of such a model with inducible activation of specific is possible that a simple dimerization of ErbB1 is not sufficient homo-and heterodimers of different ErbB receptors would be for morphological transformation whereas dimerization of very useful in understanding the early events of tumor progresErbB2 is sufficient. Consistent with that possibility, the Va1664-sion in adult animals.
Glu mutation in ErbB2 promotes homodimerization, activaThe biological effects of ErbB1 homodimerization in fibrotion of the kinase, and transformation of fibroblasts (75) . Inblasts or other cell types are unclear, since almost all cell types terestingly, the insertion of a similar mutation into ErbB1 does express more than one member of the ErbB receptor family.
not result in the ligand-independent transformation of fibroPrevious reports have shown that ErbB1 is able to induce focus blasts (15, 38, 46) , suggesting that homodimerization of ErbB1 formation in a ligand-dependent manner in NIH 3T3 clones may not be sufficient for transformation. Our results suggest which either lack ErbBl1 (21) or lack expression of all ErbB that the p75.B1.F2.HA chimera, which contains two copies of family members (79) and that EGF-activated ErbB1 possesses FKBP, can induce only a weak transformation. It should be weaker focus-forming activity than activated ErbB2 (21) . It is noted that two FKBP-containing chimeras can form higherpossible that these cell lines are not devoid of ErbB receptors, order complexes; however, sucrose gradient centrifugation of and the observed phenotype may be a result of heterodimers p75.B1.F2.HA-expressing cell lysate showed a ligand-depeninvolving ErbBl. Studies using ErbB receptor-deficient hemodent formation of a dimeric complex (data not shown). Further poietic cells that require interleukin 3 for survival and growth experiments are required to better understand the difference have suggested that ErbBl1 homodimers are not effective in between the ErbBl1 chimeras consisting of one or two copies of inducing proliferation but can induce interleukin 3-indepen-FKBP. dent survival (56). The approach presented here enables us to
We will not be able to use the heterodimerizing ligand rapastudy the effect of homodimers in the absence of lateral or mycin in biological studies since rapamycin is a known imcombinatorial interactions with other ErbB family members in munosuppressive drug that can negatively regulate cellular cells that naturally express these receptors; hence, we believe kinases FRAP and p70s 6 K. However, synthetic versions of that our observations provide a clear demonstration of the rapamycin ("rapalogs") have been generated which do not biological differences between ErbB1 and ErbB2 homodimers bind endogenous FRAP and instead can only bind to a FRAP in fibroblasts (see below), molecule that has been appropriately engineered to fit the It is unclear why synthetic ligand-induced ErbBl1 homomodification on rapamycin (18a, 43). These rapalogs possess dimers possess a five-to sevenfold weaker focus-forming acno immunosuppressive functions (18a, 43) . We are in the protivity than ErbB2 homodimers. It is possible that ErbBl1 hocess of constructing ErbB chimeras with the modified FRB modimers do not activate signaling molecules that mediate domain which will enable us to study the biological effects of transformation as effectively as ErbB2 (58) . Alternatively, the distinct ErbB heterodimers. homodimers may couple to negative regulators of signaling.
To our knowledge the results presented here provide the The heterodimerization of ErbB1 with other ErbB receptors first direct evidence for differential signaling by ErbB1 homoeither can generate novel autophosphorylation sites for actidimers and ErbBl1-ErbB2 heterodimers. It will be of interest to vating cytoplasmic signaling molecules or may fail to generate apply this strategy to understand the signaling specificities of certain autophosphorylation sites to preclude interactions with different ErbB receptor homo-and heterodimers. Since the a negative regulator(s). We present evidence which suggests synthetic ligand-mediated activation of chimeric ErbB recepthat ErbB1 homodimers and ErbBl1-ErbB2 heterodimers differ tors is independent of the endogenous levels of ErbB receptor in their abilities to recruit a cytoplasmic signaling protein, expression, this approach could be well suited to study the c-Cbl. It is possible that such differences may play a role in biological effects of different ErbB receptor dimers in the cell determining the biological specificity of homo-and heterotype of choice. dimers.
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